6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04193527 (ClinicalTrials.gov) | June 18, 2020 | 2/12/2019 | A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients | A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls | Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP) | Drug: DaTSCAN™ Ioflupane (123I) Injection | GE Healthcare | PPD | Completed | 40 Years | 80 Years | All | 172 | Phase 3 | China |
| 2 | NCT03675282 (ClinicalTrials.gov) | August 14, 2018 | 5/9/2018 | Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls | Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls | Parkinson Disease;REM Sleep Behavior Disorder;Healthy | Drug: (11C)PE2I;Drug: Ioflupane | Weill Medical College of Cornell University | National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 20 Years | 100 Years | All | 82 | Phase 1/Phase 2 | United States |
| 3 | NCT03531086 (ClinicalTrials.gov) | January 19, 2018 | 8/5/2018 | Idiopathic Parkinson's Progression and Dopamine Transporter SPECT | Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease | Parkinson Disease | Drug: Ioflupane I 123 | Julie Gurwell | NULL | Active, not recruiting | 40 Years | 75 Years | All | 12 | United States | |
| 4 | EUCTR2015-003045-26-SE (EUCTR) | 23/10/2015 | 15/09/2015 | Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease. | [18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease. | Patients with newly clinically diagnosed untreated idiopathic parkinsonism MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: [18F]FE-PE2I INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane Trade Name: DaTSCAN INN or Proposed INN: IOFLUPANE (123I) Product Name: 15O H2O INN or Proposed INN: [15O]H2O | Umeå University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 105 | Phase 2 | Sweden | ||
| 5 | NCT02138682 (ClinicalTrials.gov) | July 2014 | 24/4/2014 | Validation of DaTscan for Detection of Parkinson Disease Related Disorders | Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue | Parkinson Disease;Movement Disorders | Drug: l-123 Ioflupane | Wisconsin Institute for Neurologic and Sleep Disorders S.C. | Wisconsin Parkinson Association;Medical College of Wisconsin;GE Healthcare | Enrolling by invitation | 75 Years | N/A | Both | 20 | United States | |
| 6 | EUCTR2010-019894-13-IT (EUCTR) | 17/02/2012 | 02/03/2012 | The Parkinson's Progression Markers Initiative (PPMI) | The Parkinson's Progression Markers Initiative (PPMI) - PPMI | Parkinson Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Trade Name: DaTSCAN INN or Proposed INN: IOFLUPANE (123I) | MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Italy;United States | |||
| 7 | NCT00940914 (ClinicalTrials.gov) | March 2009 | 16/7/2009 | Dopaminergic Loss and Pain in Parkinson's Disease | Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain | Parkinson's Disease;Pain | Drug: ioflupane 123I (DATSCAN®) | University Hospital, Toulouse | NULL | Completed | 30 Years | 70 Years | All | 20 | Phase 2 | France |
| 8 | EUCTR2004-001485-41-GB (EUCTR) | 26/07/2005 | 21/06/2005 | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). | Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: carbidopa/levodopa Trade Name: Cabaser Product Name: Cabaseril INN or Proposed INN: Cabergoline Trade Name: DaTSCAN Product Name: DatSCAN INN or Proposed INN: Ioflupane [123 I] | Institute for Neurodegenerative Disorders | NULL | Not Recruiting | Female: yes Male: yes | 120 | United Kingdom;Spain | |||
| 9 | EUCTR2004-001485-41-ES (EUCTR) | 28/04/2005 | 30/01/2006 | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease | Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). | Trade Name: SINEMET Product Name: carbodopa/levadopa INN or Proposed INN: CARBODOPA LEVADOPA Trade Name: SOLIGEN Product Name: Cabergoline INN or Proposed INN: CABERGOLINA Trade Name: DaTSCAN INN or Proposed INN: Ioflupane [123I] | Institute for Neurodegenerative Disorders | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | United Kingdom;Spain | |||
| 10 | EUCTR2004-001485-41-AT (EUCTR) | 20/04/2005 | 16/03/2005 | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A | Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). | Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: carbidopa/levodopa Trade Name: Cabaseril Product Name: Cabaseril INN or Proposed INN: Cabergoline Trade Name: DaTSCAN Product Name: DatSCAN INN or Proposed INN: Ioflupane [123 I] | Institute for Neurodegenerative Disorders | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Spain;Austria;United Kingdom |